was not inferiorly effective in the prevention of thrombotic events in comparison with the unspecific cytoreductive compound hydroxyurea in the ANAHYDRET study which included exclusively WHO-classified patients with ET. 5, 6 A retrospective analysis of a large anagrelide-treated thrombocythemic MPN patient cohort suggests that both elevated WBC and elevated PLT counts during follow-up are associated with a statistically significant elevated rate of thrombosis. 7 Otherwise, near to normal values of PLT and WBC counts are associated with the lowest rate of thrombosis, whereas lowering of only one parameter is suboptimal when the other parameter is still elevated. Until now, no data exist on the need of WBC normalization when PLT count is normalized in thrombocythemic MPN patients. It was the aim of this study to investigate whether an isolated elevation of WBC count has any impact on the rate of thrombosis in patients with an already optimized PLT count. In the three patients with thrombotic events who belonged to the group with WBC counts below the calculated cutoff of 9.66 G/L, individual WBC counts immediately before a major event were also below this cutoff value. However, in all seven patients with thrombotic events who belonged to the group with WBC counts above the calculated cutoff of 9.66 G/L, individual WBC counts immediately before a major event were markedly above the calculated cutoff of 
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These data show that ET patients with optimized platelet counts during follow-up on anagrelide treatment and lower WBC counts have the lowest rate of thrombotic events. In addition, it is shown that a sustained elevation of WBC counts above the calculated threshold level of 9.66 G/L during follow-up, despite optimized PLT counts, has a clear influence on major thrombotic events. We can as has been shown in previous studies. 4 The present study is the first investigation in a prospectively observed and retrospectively analyzed large patient cohort, which was treated in a homogenous way allowing us to evaluate an effect of a single parameter on thrombophilia. However, multiple testing in the present cohort only allows drawing conclusions in a hypothetical manner, and prospective studies would be necessary to confirm these hypotheses. Our study underscores the importance of a correct diagnosis according to the WHO classification to distinguish ET from prefibrotic primary myelofibrosis. In patients without elevated WBC counts, which are more likely to be found in WHO diagnosed ET, it is sufficient to selectively lower platelet counts to prevent thrombotic events.
